vers la météo de la validation par utilisateur

Ingenuity407


precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 85 - PMID ?

Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .


Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante


Commentaires :

Analyse 0
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 1
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 2
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 3
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 4
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 5
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 6
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 7
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 8
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 9
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 10
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 11
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 12
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 13
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 14
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 15
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 16
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 17
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 18
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 19
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 20
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 21
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 22
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 23
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 24
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 25
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 26
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 27
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 28
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 29
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 30
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 31
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 32
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 33
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 34
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 35
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 36
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 37
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 38
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 39
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 40
                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 41
                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 42
                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 43
                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 44
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 45
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 46
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 47
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 48
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 49
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 50
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 51
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 52
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 53
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 54
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 55
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 56
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 57
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 58
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 59
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 60
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 61
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 62
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 63
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 64
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 65
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 66
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 67
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 68
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 69
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 70
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 71
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 72
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 73
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 74
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 75
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 76
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 77
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 78
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 79
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 80
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 81
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 82
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 83
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 84
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 85
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 86
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 87
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 88
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 89
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 90
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 91
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 92
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 93
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 94
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 95
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 96
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 97
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 98
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 99
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 100
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 101
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 102
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 103
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 104
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 105
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 106
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 107
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 108
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 109
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 110
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 111
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 112
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 113
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 114
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 115
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 116
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 117
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 118
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 119
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 120
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 121
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 122
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 123
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 124
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 125
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 126
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 127
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 128
                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 129
                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 130
                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 131
                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 132
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 133
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 134
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 135
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 136
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 137
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 138
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 139
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 140
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 141
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 142
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 143
                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 144
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 145
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 146
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 147
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 148
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 149
                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 150
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 151
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 152
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 153
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 154
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 155
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 156
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 157
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 158
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 159
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 160
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 161
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 162
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 163
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 164
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 165
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 166
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 167
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 168
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 169
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 170
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 171
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 172
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 173
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 174
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 175
                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)